Regencell Bioscience Holdings Ltd EBITDA Ratio 5 year CAGR is 90.01% for the quarter ending September 30, 2022. EBITDA Ratio is the ratio of EBITDA to revenue, indicating the operating profitability and efficiency of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.